Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference
Telo Genomics (OTCQB: TDSGF) announced its participation in the upcoming OTCQB Venture Virtual Investor Conference on August 7th, 2025. Guido Baechler, Executive Chairman of the Board, will present the company's strategy for accelerating development and commercialization of multiple myeloma MRD and smoldering myeloma assay applications.
The live, interactive presentation is scheduled for 1:00 PM - 1:30 PM ET, allowing investors to engage directly with the company through a Q&A session. An archived webcast will be available for those unable to attend the live event.
Telo Genomics (OTCQB: TDSGF) ha annunciato la sua partecipazione alla prossima Conferenza Virtuale per Investitori OTCQB Venture che si terrà il 7 agosto 2025. Guido Baechler, Presidente Esecutivo del Consiglio di Amministrazione, presenterà la strategia dell'azienda per accelerare lo sviluppo e la commercializzazione delle applicazioni per il dosaggio della MRD nel mieloma multiplo e del mieloma smoldering.
La presentazione dal vivo e interattiva è programmata per le 13:00 - 13:30 ET, offrendo agli investitori l'opportunità di interagire direttamente con l'azienda durante una sessione di domande e risposte. Per chi non potrà partecipare all'evento in diretta, sarà disponibile una registrazione webarchivata.
Telo Genomics (OTCQB: TDSGF) anunció su participación en la próxima Conferencia Virtual para Inversionistas OTCQB Venture el 7 de agosto de 2025. Guido Baechler, Presidente Ejecutivo de la Junta Directiva, presentará la estrategia de la empresa para acelerar el desarrollo y la comercialización de aplicaciones para el ensayo de MRD en mieloma múltiple y mieloma latente.
La presentación en vivo e interactiva está programada de 1:00 PM a 1:30 PM ET, permitiendo a los inversionistas interactuar directamente con la empresa mediante una sesión de preguntas y respuestas. Para quienes no puedan asistir en vivo, habrá una transmisión archivada disponible.
Telo Genomics (OTCQB: TDSGF)는 2025년 8월 7일에 개최되는 OTCQB 벤처 가상 투자자 회의에 참여한다고 발표했습니다. 이사회 집행 의장인 Guido Baechler가 다발성 골수종 MRD 및 잠복성 골수종 검사 응용 프로그램의 개발 및 상용화 가속화 전략을 발표할 예정입니다.
라이브 인터랙티브 발표는 동부시간 기준 오후 1시부터 1시 30분까지 예정되어 있으며, 투자자들은 Q&A 세션을 통해 회사와 직접 소통할 수 있습니다. 생중계에 참석하지 못하는 분들을 위해 녹화된 웹캐스트가 제공될 예정입니다.
Telo Genomics (OTCQB : TDSGF) a annoncé sa participation à la prochaine Conférence virtuelle des investisseurs OTCQB Venture qui se tiendra le 7 août 2025. Guido Baechler, Président exécutif du conseil d'administration, présentera la stratégie de l'entreprise pour accélérer le développement et la commercialisation des applications de tests MRD du myélome multiple et du myélome smoldering.
La présentation en direct et interactive est prévue de 13h00 à 13h30 ET, permettant aux investisseurs d'échanger directement avec l'entreprise lors d'une session de questions-réponses. Un webinaire archivé sera disponible pour ceux qui ne pourront pas assister à l'événement en direct.
Telo Genomics (OTCQB: TDSGF) gab seine Teilnahme an der bevorstehenden OTCQB Venture Virtual Investor Conference am 7. August 2025 bekannt. Guido Baechler, Executive Chairman des Vorstands, wird die Unternehmensstrategie zur Beschleunigung der Entwicklung und Kommerzialisierung von MRD- und schwelenden Myelom-Assay-Anwendungen präsentieren.
Die Live-Interaktive Präsentation ist für 13:00 - 13:30 Uhr ET geplant und ermöglicht Investoren eine direkte Interaktion mit dem Unternehmen während einer Fragerunde. Für diejenigen, die nicht live teilnehmen können, wird ein archivierter Webcast verfügbar sein.
- None.
- None.
Toronto, Ontario--(Newsfile Corp. - August 5, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that it will present at the OTCQB Venture Virtual Investor Conference on August 7th, 2025.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. Telo Genomics will be represented by Guido Baechler, Executive Chairman of the Board, and discuss the company's new strategy for accelerating the development and commercialization of the multiple myeloma MRD and smoldering myeloma assay applications.
The OTCQB Venture Virtual Investor Conference is hosted by VirtualInvestorConferences.com. Telo Genomics will present live on Thursday, August 7th at 1:00 pm – 1:30 pm ET. Investors can register for the presentation via this link: register here. An archived webcast will also be available after the event.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Guido Baechler
Executive Chairman
647-477-9365
info@telodx.com
MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261330
FAQ
When is Telo Genomics (TDSGF) presenting at the OTCQB Venture Virtual Investor Conference?
Who will represent Telo Genomics at the OTCQB conference?
What topics will Telo Genomics (TDSGF) discuss at the investor conference?
How can investors access Telo Genomics' OTCQB conference presentation?
